Menu Back toSession-6-Innovative-Business-Models

Pediatric Drug Development Workshop

Session 6: Innovative Business Models For Pediatric Therapeutic Development

Session Chair(s)

Thomas  Miller, PhD

Thomas Miller, PhD

  • Vice President and Global Head, Pediatrics
  • Bayer, United States
Christina  Bucci-Rechtweg, MD

Christina Bucci-Rechtweg, MD

  • Global Head, Maternal Health and Pediatric Regulatory Policy
  • Novartis Pharmaceuticals Corporation, United States
In recent years, deliberate prioritization of medication development for children has accelerated broadly across the life sciences ecosystem. This session will explore evolving, innovative business models for pediatric therapeutics. Presentations will focus on the increasingly important role of key stakeholders including large pharma, venture capital, and new academic medical center business models relating to pediatric therapeutics development. Presentations will be followed by an engaging panel discussion.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Gain the growing role of pediatric therapeutics development in the life sciences ecosystem
  • Understand how companies make decisions regarding inclusion of pediatric development programs within their portfolios
  • Understand the unique, evolving and important roles of large Pharma, Venture Capital, and Academic Institutions play towards the advancement of new medications for children


Thomas  Miller, PhD

Pharma Portfolio Considerations for Pediatric Development Programs

Thomas Miller, PhD

  • Vice President and Global Head, Pediatrics
  • Bayer, United States
Gavin  Miyasato, MS

TRINITY Whitepaper: What We Value – the Proposition Behind the Price

Gavin Miyasato, MS

  • Associate Director of Statistics
  • TRINITY, United States
Daniel  Fields, JD

Redefining the Approach for Pediatric Academic Medical Centers

Daniel Fields, JD

  • Vice President, Business Innovation
  • Children’s Hospital of Philadelphia, United States